Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-15
2008-04-15
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
11780988
ABSTRACT:
This invention relates to CCK-A agonists of Formula (I)wherein R1-R4, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating diabetes.
REFERENCES:
patent: 4080323 (1978-03-01), Walser et al.
patent: 5646140 (1997-07-01), Sugg et al.
patent: 5798353 (1998-08-01), Badorc et al.
patent: 2426305 (1973-01-01), None
patent: 2318673 (1974-11-01), None
patent: 2813549 (1978-10-01), None
patent: 1470803 (1974-05-01), None
patent: 7803585 (1977-10-01), None
patent: WO9528391 (1995-10-01), None
patent: WO9528419 (1995-10-01), None
patent: WO0068209 (2000-11-01), None
Smith, G. P. et al., Science, vol. 213, Aug. 28, 1981, pp. 1036-1037, “Abdominal Vagotomy Blocks the Satiety Effect of Cholecystokinin in the Rat”.
Crawley J. N. et al., J. Pharmacol. Exp. Ther., vol. 257, Issue 3, pp. 1076-1080, Jun. 1, 1991, “Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism”.
Gibbs J. et al., Journal of Comparative Physiological Psychology, vol. 84, No. 3, pp. 488-495, 1973, “Cholecystokinin Decreases Food Intake in Rats”.
Himick B. A. et al., American Physiological Society, vol. 267, pp. R841-R851, 1994, “CCK/gastrin-like immunoreactivity in brain and gut, and CCK suppression of feeding in goldfish”.
Hirosue Y. et al., American Physiological Society, vol. 265, pp. R481-R486, 1993, “Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice”.
Asin K. E. et al., Pharmacology Biochemistry and Behavior, vol. 42, pp. 699-704, 1992, “A-71623, a Selective CCK-A Receptor Agonist, Suppresses Food Intake in the Mouse, Dog, and Monkey”.
Chow, et al., “Fused Heterocycles from Substituted 1, 3, 4, 5-Tetrahydro-1-phenyl-4-thioxo-8-(trifluoromethyl)-2H-1, 5-benzodiazepin-2-ones,” Applebrook Research Center, Animal Health Products Divisions, SmithKline Corporation, West Chester, PA 19380, USA; vol. 13, pp. 163-167, Feb. 1976.
Darrow, et al., “Structurally similar small molecule photoaffinity CCK-A agonists and antagonists as novel tools for directly probing 7TM receptor-ligand interactions,” Science Direct—Bioorganic & Medicinal chemistry Letters, Abstract available online Feb. 16, 1999.
Cabeza, et al., “Formation of a Highly Functionalized Azulene Ligand by Metal Cluster-Mediated Coupling of Three Conjugated Diyness,” Organometallics, 2003, 22, pp. 1164-1166.
Sugg E. E. et al., Pharmaceutical Biotechnology, vol. 11, pp. 507-524, 1998, “Integration of Pharmaceutical Discovery and Development”.
Sherrill R. G. et al., Bioorganic & Medicinal Chemistry Letters, vol. 11(9), pp. 1145-1148, 2001, “1,4-Benzodiazepine Peripheral Cholecystokinin (CCK-A) Receptor Agonists”.
Henke B. R. et al., J. Med. Chem., vol. 40(17), pp. 2706-2725, 1997, “Optimization of 3-(3H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists”.
Henke B. R. et al., J. Med. Chem., vol. 39(14), pp. 2655-2658, 1996, “3-(1H-Indazol-3-ylmethyl)-1,5-benzo-diazepines: CCK-A Agonists That Demonstrate Oral Activity as Satiety Agents”.
Langlois M. et al., J. Heterocyclic Chem. vol. 19(1), pp. 193-200, 1982. “Synthese de nouvelles amidines bicycliques. 1. Derives de l'imidazole, du triazole-1,3,4 et du tetrazole”.
English Language Equivalent for DE2318673 is GB1462095.
English Language Equivalent for DE2426305 is US4164498.
Bignon, et al., “SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. II: In Vivo Pharmacological Characterization,” JPET 289: 752-761, 1999.
Cameron Kimberly O.
Elliott Richard L.
Hammond Marlys
Benson Gregg C.
Kennedy Robert M.
Kifle Bruck
Pfizer Inc.
LandOfFree
Tetraazabenzo[e]azulene derivatives and analogs thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetraazabenzo[e]azulene derivatives and analogs thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetraazabenzo[e]azulene derivatives and analogs thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3958397